In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

a combined drug that has an antitussive, mucolytic and expectorant effect. citrate, which is part of the preparation of butamirate, belongs to antitussive substances of peripheral action, does not cause dependence, does not inhibit the respiratory center.

The antitussive effect of butamirate citrate is supplemented by an expectorant effect of guaifenesin, which enhances the secretion of bronchial glands, reduces the viscosity of sputum and thereby improves its discharge.

Pharmacokinetics Butamyrate citrate after oral administration is rapidly and completely absorbed, is 98% bound to plasma proteins. It is metabolized with the formation of two metabolites that have an antitussive effect, more than 90% of which is excreted in the urine; only a small amount is excreted in the feces. Biological T½ is about 6 hours

Guaifenesin after oral administration is rapidly absorbed in the digestive tract. An insignificant part of it binds to plasma proteins. Excreted in the urine, mainly in the form of metabolites, a small amount - unchanged. Biological T½ is 1 hour


Dry, irritating, paroxysmal cough of various origins. the drug can be used to eliminate cough in the pre- and postoperative period.


Apply inside. preferably after a meal. Dissolve the appropriate number of drops in 100 ml of liquid (water, tea, fruit juice). the interval between doses should be 4-6 hours.

You should adhere to the dosage depending on the patient’s body weight:

  • up to 7 kg - 8 drops 3-4 times a day;
  • 7-12 kg - 9 drops 3-4 times a day;
  • 12–20 kg - 14 drops 3-4 times a day;
  • 20-30 kg - 14 drops 3-4 times a day;
  • 30-40 kg - 16 drops 3-4 times a day;
  • 40-50 kg - 25 drops 3 times a day;
  • 50–70 kg - 30 drops 3 times a day;
  • 70–90 kg - 40 drops 3 times a day.

The maximum daily dose of guaifenesin for children aged 6 months to 2 years is 300 mg / day (3 ml of the drug, or 99 drops), for children aged 2-6 years, 600 mg / day (6 ml of the drug, or 198 drops ), 6-12 years old - 1200 mg / day (12 ml of the drug), for adults and children over the age of 12 years - 2400 mg / day (24 ml of the drug).

Taking more fluid increases the effectiveness of the treatment. If Pectolvan Stop is prescribed for very young children (weighing 7 kg), then the dose can be reduced. Even if the child does not drink all 100 ml of the liquid with the drug dissolved in it, you can not increase the number of drops of the drug (total concentration) in the liquid.

Do not use the drug for longer than 7 days without consulting a doctor.


Hypersensitivity to the components of the drug, myasthenia gravis.

Side effects

If you adhere to the recommended dosage, the drug is usually well tolerated. side effects usually disappear after a dose reduction.

From the side of metabolism: lack of appetite;

from the nervous system: headache, drowsiness;

on the part of the organ of hearing and balance: dizziness;

on the part of the respiratory system: shortness of breath;

from the digestive tract: discomfort in the digestive tract, nausea, pain in the stomach, vomiting, diarrhea;

from the urinary system: urolithiasis;

from the immune system: allergic reactions, including anaphylactic shock, angioedema, skin rashes, itching, urticaria.

special instructions

The drug should not be used in patients with BA, chronic bronchitis or emphysema, productive cough and / or persistent or chronic cough associated with smoking.

Use with caution the drug for tuberculosis, pneumoconiosis.

If the cough persists or intensifies, treatment should be reviewed.

Pectolvan Stop contains 34.3 vol.% Ethanol (alcohol), that is, up to 350 mg when taking the maximum single dose (40 drops), which is equivalent to approximately 8 ml of beer or 3 ml of wine when taking the maximum single dose. This can have undesirable consequences for patients with alcoholism. The presence of ethanol should be considered in the treatment of pregnant or breast-feeding, as well as children and people at high risk, such as patients with liver disease or epilepsy.

If you are intolerant of certain sugars, you should consult your doctor before taking this medicine.

Use during pregnancy and lactation. Controlled studies involving pregnant or animals have not been conducted. An increase in the number of cases of inguinal hernia in newborns with the use of guaifenesin in the first trimester of pregnancy has been reported. Therefore, the drug is contraindicated in the first trimester of pregnancy.

The use of the drug in the second and third trimester of pregnancy or during lactation is possible only in cases where, according to the doctor, the expected therapeutic effect for the mother outweighs the potential risk to the fetus / baby.

It is not known whether citrate or guaifenesin passes into breast milk. For safety reasons, it is necessary to carefully weigh the benefits and risks of using the drug during lactation.

Children. The drug can be used in children from 6 months of age in accordance with the indications.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Rarely, the drug can cause drowsiness, which can to some extent affect the ability to drive vehicles or work in other mechanisms. Therefore, when driving a car or performing other work that requires care (for example, when controlling mechanical means), you should be careful.


Since butamirate inhibits the cough reflex, it is necessary to avoid the simultaneous use of expectorants, as this can lead to stagnation of mucus in the airways, which increases the risk of bronchospasm and respiratory tract infection.

Lithium and magnesium enhance the effect of guaifenesin.

Guaifenesin enhances the analgesic effect of paracetamol and acetylsalicylic acid, enhances the effect of alcohol and other substances that depress the central nervous system.

Muscle relaxants with a central mechanism of action can enhance the unwanted effects of guaifenesin, especially muscle weakness.

Guaifenesin can cause false positive results of diagnostic tests for the determination of 5-hydroxyindoleacetic acid (photometric method using nitrosonaphthol as a reagent) and vanillyl mandelic acid in the urine. It is necessary to stop treatment with Pectolvan Stop 48 hours before urine collection for this analysis.


In case of an overdose, signs of the toxic effect of guaifenesin predominate - drowsiness, nausea, vomiting, muscle weakness.

Overdose symptoms such as diarrhea, dizziness, arterial hypotension may also be observed. X-ray negative urolithiasis is possible.

There is no specific antidote.

Treatment. Gastric lavage, intake of activated carbon. Symptomatic therapy is aimed at maintaining the functions of the cardiovascular and respiratory systems, kidney function and electrolyte balance.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° c. do not freeze.

Tags: Butamirat, Guaifenesin